By Sabela Ojea
Shares of UroGen Pharma surged on Thursday after the biotechnology company said Phase 3 trials for its bladder cancer investigational treatment UGN-102 are fully enrolled.
The stock was up 49% to $13.37 at 11:18 a.m. ET. The shares have jumped 62% in the past 12 months.
The company said completing enrollment for the study is a major milestone that brings them one step closer validation of the medication for low-grade intermediate-risk nonmuscle-invasive bladder cancer.
UroGen expects to submit a New Drug Application with the Food and Drug Administration for the treatment UGN-102 in 2024.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
07-27-23 1151ET